Dare Bioscience, Inc. logo

Dare Bioscience, Inc. (DARE) Q1 2026 Earnings

DARE·Reported May 14, 2026·After market close

Dare Bioscience, Inc. reported Q1 2026 revenue of $152.5K (+499.6% YoY), beat analyst consensus of $27.0K by $125.5K. Diluted EPS came in at $-0.20 (+60.0% YoY), beat the $-0.33 consensus by $0.13.

Revenue
$152.5Kbeat by $125.5K
Consensus: $27.0K
Diluted EPS
$-0.20beat by $0.13
Consensus: $-0.33
SEC

SEC Filings

Earnings release8-K · 0001401914-26-000025
Quarterly report10-Q · 0001401914-26-000026

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Dare Bioscience, Inc.'s Q1 2026 earnings report.

Dare Bioscience, Inc. (DARE) reported Q1 2026 earnings on May 14, 2026 after market close.

Dare Bioscience, Inc. reported revenue of $152.5K and diluted EPS of $-0.20 for Q1 2026.

Revenue beat the consensus estimate of $27.0K by $125.5K. EPS beat the consensus estimate of $-0.33 by $0.13.

Compared to the same quarter a year prior, revenue grew 499.6% from $25.4K a year earlier and diluted EPS grew 60.0% from $-0.50.

You can read the 8-K earnings release (0001401914-26-000025) and the 10-Q periodic report (0001401914-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.